LYPHF
Price
$0.27
Change
+$0.01 (+3.85%)
Updated
Apr 11 closing price
Capitalization
1.76B
VRBCF
Price
$324.00
Change
-$0.55 (-0.17%)
Updated
Mar 31 closing price
Capitalization
2.61B
Ad is loading...

LYPHF vs VRBCF

Header iconLYPHF vs VRBCF Comparison
Open Charts LYPHF vs VRBCFBanner chart's image
Luye Pharma Group
Price$0.27
Change+$0.01 (+3.85%)
Volume$3.73K
Capitalization1.76B
Virbac SA
Price$324.00
Change-$0.55 (-0.17%)
Volume$7
Capitalization2.61B
LYPHF vs VRBCF Comparison Chart
Loading...
View a ticker or compare two or three
VS
LYPHF vs. VRBCF commentary
Apr 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LYPHF is a Hold and VRBCF is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 19, 2025
Stock price -- (LYPHF: $0.27 vs. VRBCF: $324.00)
Brand notoriety: LYPHF and VRBCF are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: LYPHF: 352% vs. VRBCF: 12%
Market capitalization -- LYPHF: $1.76B vs. VRBCF: $2.61B
LYPHF [@Pharmaceuticals: Major] is valued at $1.76B. VRBCF’s [@Pharmaceuticals: Major] market capitalization is $2.61B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LYPHF’s FA Score shows that 0 FA rating(s) are green whileVRBCF’s FA Score has 0 green FA rating(s).

  • LYPHF’s FA Score: 0 green, 5 red.
  • VRBCF’s FA Score: 0 green, 5 red.
According to our system of comparison, VRBCF is a better buy in the long-term than LYPHF.

Price Growth

LYPHF (@Pharmaceuticals: Major) experienced а +5.02% price change this week, while VRBCF (@Pharmaceuticals: Major) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.49%. For the same industry, the average monthly price growth was -6.12%, and the average quarterly price growth was -11.03%.

Industries' Descriptions

@Pharmaceuticals: Major (+3.49% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

FUNDAMENTALS
Fundamentals
VRBCF($2.61B) has a higher market cap than LYPHF($1.76B). VRBCF has higher P/E ratio than LYPHF: VRBCF (29.33) vs LYPHF (19.23). VRBCF YTD gains are higher at: -4.490 vs. LYPHF (-22.025). LYPHF has higher annual earnings (EBITDA): 907M vs. VRBCF (213M). LYPHF has more cash in the bank: 5.51B vs. VRBCF (176M). VRBCF has less debt than LYPHF: VRBCF (148M) vs LYPHF (9.49B). LYPHF has higher revenues than VRBCF: LYPHF (5.2B) vs VRBCF (1.15B).
LYPHFVRBCFLYPHF / VRBCF
Capitalization1.76B2.61B67%
EBITDA907M213M426%
Gain YTD-22.025-4.490491%
P/E Ratio19.2329.3366%
Revenue5.2B1.15B452%
Total Cash5.51B176M3,131%
Total Debt9.49B148M6,413%
FUNDAMENTALS RATINGS
VRBCF: Fundamental Ratings
VRBCF
OUTLOOK RATING
1..100
36
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
PROFIT vs RISK RATING
1..100
53
SMR RATING
1..100
54
PRICE GROWTH RATING
1..100
71
P/E GROWTH RATING
1..100
80
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PRGSX58.050.64
+1.11%
T. Rowe Price Global Stock
PGWIX9.820.07
+0.72%
Principal MidCap Growth Inst
ALTFX128.280.72
+0.56%
AB Sustainable Global Thematic A
SVIIX8.830.02
+0.23%
Virtus Ceredex Large-Cap Value Equity A
VSQSX15.190.01
+0.07%
Invesco MSCI World SRI Index R6

LYPHF and

Correlation & Price change

A.I.dvisor tells us that LYPHF and OGN have been poorly correlated (+4% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LYPHF and OGN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LYPHF
1D Price
Change %
LYPHF100%
N/A
OGN - LYPHF
4%
Poorly correlated
+2.77%
SNYNF - LYPHF
3%
Poorly correlated
+2.96%
CSWYF - LYPHF
1%
Poorly correlated
N/A
VRBCF - LYPHF
-0%
Poorly correlated
N/A
JCRRF - LYPHF
-1%
Poorly correlated
N/A
More

VRBCF and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRBCF has been loosely correlated with RCDTF. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if VRBCF jumps, then RCDTF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRBCF
1D Price
Change %
VRBCF100%
N/A
RCDTF - VRBCF
56%
Loosely correlated
N/A
OGN - VRBCF
1%
Poorly correlated
+2.77%
MIRA - VRBCF
1%
Poorly correlated
-12.25%
CSWYF - VRBCF
0%
Poorly correlated
N/A
JCRRF - VRBCF
-0%
Poorly correlated
N/A
More